General Information of Drug (ID: DMXI9P4)

Drug Name
EPX-100 Drug Info
Indication
Disease Entry ICD 11 Status REF
Dravet syndrome 8A61.11 Phase 1 [1]
Cross-matching ID
PubChem CID
5309446
TTD Drug ID
DMXI9P4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting 5-HT receptor (5HTR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [2]
Paliperidone DM7NPJS Psychotic disorder 6A20-6A25 Approved [3]
Ramosetron DMH7GN8 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [2]
Pizotyline DMV74ZH Headache 8A80-8A84 Approved [3]
Tandospirone DMPHWU6 Anxiety disorder 6B00-6B0Z Approved [2]
Nafronyl DMVMQ1L Cerebrovascular ischaemia 8B1Z Approved [3]
ITI-007 DMUQ1DO Depression 6A70-6A7Z Phase 3 [4]
Fenfluramine DM0762O Dravet syndrome 8A61.11 Phase 3 [5]
MIN-117 DMSLIW6 Major depressive disorder 6A70.3 Phase 2 [4]
Lu-AA34893 DM2ZUXK Anxiety disorder 6B00-6B0Z Phase 2 [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT receptor (5HTR) TT85JO3 NOUNIPROTAC Modulator [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
6 Encyclopedia of Psychopharmacology. Ian Stolerman. 2010. Page(105).